

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jacobson Pharma Corporation Limited

雅各臣科研製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Stock Code : 2633

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT OF THE COMPANY FOR THE YEAR ENDED 31 MARCH 2021

Reference is made to the annual report of Jacobson Pharma Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) for the year ended 31 March 2021 (the “**2021 Annual Report**”). Unless otherwise stated, terms used in this announcement shall have the same meanings as those defined in the 2021 Annual Report.

The Board would like to provide the following supplemental information to the paragraph headed “Continuing Connected Transactions” under the Report of the Directors as set out in the 2021 Annual Report in relation to the continuing connected transactions under Rules 14A.55 and 14A.56 of the Listing Rules:

The independent non-executive directors of the Company reviewed each of the Logistics Services Agreement, Manufacturing Services Agreement and Overseas Sales Administrative Services Agreement for the year ended 31 March 2021 (the “**Transactions**”) and confirmed that the Transactions have been entered into: (i) in the ordinary and usual course of the Group’s business; (ii) on normal commercial terms or better; and (iii) in accordance with the terms of the respective agreements governing such transactions on terms that were fair and reasonable and in the interests of the shareholders of the Company as a whole.

Pursuant to Rule 14A.56 of the Listing Rules, the Company's auditor was engaged to report on the Transactions in accordance with Hong Kong Standard on Assurance Engagements 3000 (Revised) "Assurance Engagements Other than Audits or Reviews of Historical Financial Information" and with reference to Practice Note 740 "Auditor's Letter on Continuing Connected Transactions under the Hong Kong Listing Rules" issued by the Hong Kong Institute of Certified Public Accountants. The auditor has issued their unqualified letter containing the auditor's findings and conclusions in respect of the Transactions in accordance with Rule 14A.56(1) to (3) of the Listing Rules and nothing has come to its attention that causes it to believe that the Transactions have exceeded the de minimis transactions threshold under the Rule 14A.76(1) of the Listing Rules.

The above additional information does not affect other information contained in the 2021 Annual Report and, save as disclosed in this announcement, the remaining contents of the 2021 Annual Report remain unchanged.

By Order of the Board
Jacobson Pharma Corporation Limited
Yu Chun Kau
Company Secretary

Hong Kong, 31 January 2022

As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek (also as Chairman and Chief Executive Officer), Mr. Yim Chun Leung and Ms. Pun Yue Wai as executive Directors, Professor Wong Chi Kei, Ian as non-executive Director, and Dr. Lam Kwing Tong, Alan, Mr. Young Chun Man, Kenneth and Professor Lam Sing Kwong, Simon as independent non-executive Directors.